PTX–
COVID19–B
best-in-class aim, with high safety & Tolerability profile
Through Providence’s World-Class-Scientific team, we created our first fully Made-in-Canada mRNA vaccine, PTX-COVID19-B in April 2020 at the very beginning of the global pandemic.
Through our Phase 2 Human Clinical Trial results, our vaccine has shown a response with a high level of neutralizing antibodies, while showing to be safe and effective.
Status: Completed Phase 2 Human Clinical Trial October 2022
Positive Top-Line Data from Phase 2 Primary Immunization Trial: Click here
Strategy: Generate potent neutralizing antibodies to prevent infection and promote strong immunity.
Providence’s PTX-COVID19-B aims to be the Best-In-Class, with high safety and tolerability profile.